for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Baudax Bio Inc

BXRX.OQ

Latest Trade

1.46USD

Change

-0.11(-7.01%)

Volume

1,193,342

Today's Range

1.40

 - 

1.52

52 Week Range

0.97

 - 

10.12

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.57
Open
1.51
Volume
1,193,342
3M AVG Volume
72.12
Today's High
1.52
Today's Low
1.40
52 Week High
10.12
52 Week Low
0.97
Shares Out (MIL)
42.64
Market Cap (MIL)
66.94
Forward P/E
-0.38
Dividend (Yield %)
--

Latest Developments

More

Baudax Bio Reports Third Quarter 2020 Financial Results

Baudax Bio Reports Qtrly Loss Per Share $1.72

Baudax Bio Q2 Loss Per Share $1.72 Including Items

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Baudax Bio Inc

Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.

Industry

Biotechnology & Drugs

Contact Info

490 Lapp Rd

MALVERN, PA

19355-1212

United States

https://www.baudaxbio.com/

Key Stats

1.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020(E)

0.0K
EPS (USD)

2019

-3.480

2020(E)

-4.165
Price To Earnings (TTM)
--
Price To Sales (TTM)
160.53
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-183.60
Return on Equity (TTM)
-136.24

Latest News

Latest News

BRIEF-Baudax Bio Inc Announces Commercial Launch Of Anjeso Injection

* BAUDAX BIO - RECEIPT OF UNIQUE C-CODE AND PASS-THROUGH PAYMENT STATUS EFFECTIVE JULY 1 Source text for Eikon: Further company coverage:

BRIEF-Baudax Bio Secures $50 Million Credit Facility

* BAUDAX BIO SECURES $50 MILLION CREDIT FACILITY Source text for Eikon: Further company coverage:

U.S. RESEARCH ROUNDUP-Acushnet Holdings, Equity Residential, Fiserv

Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Acushnet Holdings, Equity Residential and Fiserv, on Monday. HIGHLIGHTS * Acushnet Holdings Corp : Stephens raises target price to $27 from $24 * Equity Residential...

BRIEF-Stonepine Capital Management Llc Reports 9.99% Passive Stake In Baudax Bio

* STONEPINE CAPITAL MANAGEMENT LLC REPORTS 9.99% PASSIVE STAKE IN BAUDAX BIO INC AS OF MARCH 24 - SEC FILING Source text: (http://www.sec.gov/Archives/edgar/data/1440771/000093583620000245/0000935836-20-000245-index.htm) Further company coverage:

BRIEF-Baudax Bio Announces Proposed Public Offering Of Common Stock And Warrants

* BAUDAX BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

BRIEF-‍baudax Bio Signs Non-Binding Term Sheet For Debt Facility​

* BAUDAX BIO - SIGNED A NON-BINDING TERM SHEET WITH AN UNDISCLOSED PARTY FOR A SECURED TERM LOAN FOR UP TO $20 MILLION IN NON-DILUTIVE FUNDING

BRIEF-Baudax Bio Announces FDA Approval Of Anjeso For The Management Of Moderate To Severe Pain

* BAUDAX BIO ANNOUNCES FDA APPROVAL OF ANJESO™ FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN

BRIEF-Baudax Bio Says May Offer, Sell Shares Of Common Stock Having Aggregate Offering Price Of Up To $25 Million From Time To Time - SEC Filing

* BAUDAX BIO - MAY OFFER, SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $25 MILLION FROM TIME TO TIME - SEC FILING Source text: (http://bit.ly/2uMpgmG) Further company coverage:

BRIEF-Baudax Bio Reports 2019 Annual Financial Results

* BAUDAX BIO INC - AS OF DECEMBER 31, 2019, BAUDAX HAD CASH AND CASH EQUIVALENTS OF $17.7 MILLION Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up